Ovid Therapeutics (OVID)
(Delayed Data from NSDQ)
$0.51 USD
+0.01 (2.80%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $0.50 -0.01 (-2.00%) 4:52 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
OVID 0.51 +0.01(2.80%)
Will OVID be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for OVID based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OVID
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
Fortrea Holdings Inc. (FTRE) Q1 Earnings and Revenues Beat Estimates
OVID: What are Zacks experts saying now?
Zacks Private Portfolio Services
ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates
Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates
Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Other News for OVID
Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference | OVID Stock News
Ovid Therapeutics management to meet with B. Riley
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Thursday's Intraday Session
Upcoming B. Riley Meeting Features Key Insights for OVID Investors | OVID Stock News